M055 DEVELOPMENT OF OCCLUSIVE SINUOUS VENOUS THROMBOSIS ON SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY

Abstract

Immunoglobulin therapy is commonly used to replace deficiency in those with humoral deficiency and to modulate autoimmune and autoinflammatory disease. Routes of delivery include intravenous, intramuscular, and subcutaneous (SCIG); reported systemic adverse events include anaphylaxis, headache, fever, thrombosis, aseptic meningitis, and hemolytic anemia. SCIG has been reported to have similar efficacy with decreased risk of systemic adverse reaction compared to IV administration.